Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.38 |
| ▸ | GAK | O14976 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515404 | 0.83 | LRRK2 (0.45) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2216078 | 0.80 | KDM4E (0.42) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2215831 | 0.80 | KDM4E (0.40) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2213873 | 0.78 | LRRK2 (0.40) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2216454 | 0.78 | LRRK2 (0.46) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2216542 | 0.77 | LRRK2 (0.43) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2213462 | 0.77 | TSHR (0.38) | KDM4EHTTTSHRNPSR1GAK | |
| SCHEMBL2215921 | 0.76 | KDM4E (0.39) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2213101 | 0.76 | KMT2A (0.40) | KDM4EHTTTSHRNPSR1LRRK2 | |
| SCHEMBL2215681 | 0.76 | KDM4E (0.39) | KDM4EHTTTSHRNPSR1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | KDM4E 4617/4885HTT 3702/4885TSHR 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.